BR112019002689A2 - terapia com rapamicina tópica - Google Patents

terapia com rapamicina tópica

Info

Publication number
BR112019002689A2
BR112019002689A2 BR112019002689A BR112019002689A BR112019002689A2 BR 112019002689 A2 BR112019002689 A2 BR 112019002689A2 BR 112019002689 A BR112019002689 A BR 112019002689A BR 112019002689 A BR112019002689 A BR 112019002689A BR 112019002689 A2 BR112019002689 A2 BR 112019002689A2
Authority
BR
Brazil
Prior art keywords
rapamycin
conditions
topical rapamycin
rapamycin therapy
therapy
Prior art date
Application number
BR112019002689A
Other languages
English (en)
Inventor
A Hebert Adelaide
Northrup Hope
Kay Koenig Mary
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112019002689A2 publication Critical patent/BR112019002689A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

uma composição tópica contendo rapamicina e um carreador isento de álcool são usados para entregar rapamicina às células da pele, evitando a absorção sistêmica, permitindo o tratamento seguro e eficaz de várias condições da pele, incluindo angiofibromas que surgem de condições como o complexo de esclerose tuberosa (tsc).
BR112019002689A 2016-08-10 2017-08-10 terapia com rapamicina tópica BR112019002689A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662372940P 2016-08-10 2016-08-10
PCT/US2017/046320 WO2018031789A1 (en) 2016-08-10 2017-08-10 Topical rapamycin therapy

Publications (1)

Publication Number Publication Date
BR112019002689A2 true BR112019002689A2 (pt) 2019-05-14

Family

ID=59684091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002689A BR112019002689A2 (pt) 2016-08-10 2017-08-10 terapia com rapamicina tópica

Country Status (11)

Country Link
US (1) US20190167649A1 (pt)
EP (1) EP3496712A1 (pt)
JP (1) JP2019527711A (pt)
KR (1) KR20190039220A (pt)
CN (1) CN109689053A (pt)
AU (1) AU2017311491A1 (pt)
BR (1) BR112019002689A2 (pt)
CA (1) CA3032473A1 (pt)
MX (1) MX2019001670A (pt)
RU (1) RU2019106483A (pt)
WO (1) WO2018031789A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302385B1 (en) 2017-01-06 2024-02-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
US20210177810A1 (en) * 2018-02-06 2021-06-17 Georgetown University TOPICAL mTOR INHIBITORS FOR CUTANEOUS PROLIFERATIVE AND VASCULAR CONDITIONS
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
BR112021003497A2 (pt) * 2018-08-30 2021-05-18 Chemistryrx. composições contendo sirolimo
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
KR20210130769A (ko) 2019-02-20 2021-11-01 에이아이 테라퓨틱스, 인코포레이티드 국소 라파마이신 제형 및 안면 혈관섬유종 및 다른 피부 장애에서의 이의 용도
US20220142990A1 (en) * 2019-02-27 2022-05-12 Osaka University External preparation for treating a vascular anomaly
EP4094761A4 (en) 2020-01-24 2023-12-27 Nobelpharma Co., Ltd. EXTERNAL PREPARATION CONTAINING RAPAMYCIN
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
RU2005106855A (ru) 2002-08-12 2005-10-10 Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) Диагностика и лечение заболеваний, вызываемых дефектами каскада реакций, обусловливающих туберозный склероз
AU2006218918A1 (en) 2005-03-02 2006-09-08 Wyeth Purification of rapamycin
US20100305150A1 (en) 2006-02-02 2010-12-02 Novartis Ag Tuberous sclerosis treatment
US20120022095A1 (en) 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
ES2797376T3 (es) * 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CN115645534A (zh) * 2015-09-24 2023-01-31 德雷克塞尔大学 治疗或预防皮肤障碍的新型组合物和方法
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途

Also Published As

Publication number Publication date
KR20190039220A (ko) 2019-04-10
EP3496712A1 (en) 2019-06-19
RU2019106483A3 (pt) 2020-12-04
JP2019527711A (ja) 2019-10-03
RU2019106483A (ru) 2020-09-11
AU2017311491A1 (en) 2019-02-07
CN109689053A (zh) 2019-04-26
WO2018031789A1 (en) 2018-02-15
CA3032473A1 (en) 2018-02-15
MX2019001670A (es) 2019-07-04
US20190167649A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
BR112019002689A2 (pt) terapia com rapamicina tópica
CY1123459T1 (el) Χρηση των κανναβινοειδων στη θεραπεια του συμπλεγματος οζωδους σκληρυνσης
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
BR112017000470A2 (pt) composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção
CL2016002312A1 (es) Modulador del receptor de andrógeno y usos de este.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112017023576A2 (pt) Método para tratar uma disfunção proliferativa de células b
BR112015009189A2 (pt) conjunto de potência para um autoinjetor e autoinjetor que contém o mesmo
CR20160173A (es) Nuevo tratamiento de combinación para la leucemia mieloide aguda (lma)
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
BR112018001435A2 (pt) métodos para entrega linfática de agentes ativos
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112019024566A2 (pt) inibidores de pirazol magl
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
CL2016000026A1 (es) Nuevos derivados de azabencimidazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2735 DE 06-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.